Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.

MLA

Todesca, Paola, et al. “Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.” Hepatology (Baltimore, Md.), vol. 70, no. 2, Aug. 2019, pp. 745–47. EBSCOhost, https://doi.org/10.1002/hep.30588.

APA

Todesca, P., Marzi, L., Critelli, R. M., Cuffari, B., Caporali, C., Turco, L., Pinelli, G., Schepis, F., Carulli, L., de Maria, N., Casari, F., Scaglioni, R., & Villa, E. (2019). Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 70(2), 745–747. https://doi.org/10.1002/hep.30588

Chicago

Todesca, Paola, Luca Marzi, Rosina Maria Critelli, Biagio Cuffari, Cristian Caporali, Laura Turco, Giovanni Pinelli, et al. 2019. “Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.” Hepatology (Baltimore, Md.) 70 (2): 745–47. doi:10.1002/hep.30588.